Covington & Burling LLP | Jacqueline Clover

This website uses cookies. For more information please contact us or consult our privacy policy.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

PDF Binder
- Create PDF
- Add to Binder
Word Document Binder

Jacqueline Clover

Associate

London +44 20 7067 2283 jclover@cov.com Download V-card

View Less

Jacqueline Clover is an associate in Covington’s life sciences transactional group, having joined the firm as a trainee solicitor in 2012.

Ms. Clover's practice covers a broad range of life sciences agreements, licensing and collaboration agreements, intellectual property law and commercial matters.

Advising AstraZeneca on its agreement to transfer to the company the rights to Almirall’s respiratory franchise for an initial consideration of $875 million on completion, and up to $1.22 billion in development, launch, and sales-related milestones.
Advising a leading biopharmaceutical business on its strategic partnership for the development of certain compounds used in the treatment of Parkinson’s disease.
Advising a leading biopharmaceutical business on its consortium partnership for a research project relating to neurodegenerative diseases.
Advising Innovacell on a collaboration and licensing agreement with Norgine for Europe (excluding Russia and Turkey), SADC and MENA regions in which Innovacell and Norgine will co-develop, and Norgine will commercialise, ICEF15 - an innovative personalised cell therapy to treat faecal incontinence.
Advising a spin-out pharmaceutical company developing treatments for inflammatory diseases of the gut and eye on a range of commercial agreements.

Advising a children’s charity on a collaborative arrangement with a fostering agency for the provision of certain therapeutic and care services.
Advising an international charity on its acquisition of a microfinance bank.

Covington Advises AstraZeneca on Divestment of Rights to Rhinocort Aqua

LONDON—Covington advised AstraZeneca on its agreement with Cilag GmbH International, an affiliate of Johnson & Johnson, for the divestment of the rights to Rhinocort Aqua outside the U.S. Rhinocort Aqua is a nasal spray indicated for allergic and non-allergic rhinitis (inflammation of the inside of the nose), and for the treatment of nasal polyps (swelling of ...

Covington Advises AstraZeneca on European Rights to Moventig

LONDON — Covington advised AstraZeneca on an agreement with ProStrakan Group, a subsidiary of Kyowa Hakko Kirin Co. Ltd., for the rights to Moventig (naloxegol) in the European Union (EU), Iceland, Norway, Switzerland and Liechtenstein. Moventig is the first once-daily, oral peripherally-acting mu-opioid receptor antagonist (PAMORA) approved in Europe for the ...

Terahertz time-domain spectroscopy technology — a new tool to combat counterfeiting?

Counterfeiters are constantly coming up with new and clever ways to produce high quality copies of fashion and luxury products. Many copies can’t be distinguished from the original products without authentication features. Brands are increasingly using RFID tags and other ways to help consumers and customs officials identify what’s real and what’s fake. The ...

Representative Matters

Pro Bono

News and Insights (Showing 3 of 3) (Showing 3 of 3)

Covington Advises AstraZeneca on Divestment of Rights to Rhinocort Aqua

Covington Advises AstraZeneca on European Rights to Moventig

Terahertz time-domain spectroscopy technology — a new tool to combat counterfeiting?

Practices

Industries

Education

BPP Law School, London, L.P.C., 2012

The University of Chicago Law School, LL.M., 2010

University of Cambridge, B.A., 2006

Bar Admissions

Languages